Ipamorelin vs CJC-1295
Ipamorelin is a synthetic pentapeptide that acts as a selective agonist at growth hormone secretagogue receptor 1a, the ghrelin receptor. CJC-1295 refers to two related growth hormone-releasing hormone receptor agonists built on the N-terminal 29-amino-acid fragment of human GHRH, one carrying an albumin-binding drug affinity complex and one, more accurately called modified GRF(1-29), without it. They are constantly paired because they act on different receptors within the same axis, which is the stated rationale for combining them. Despite that, no published study has administered both to the same subjects, whether together or in parallel arms. Every claim about how the two compare, or about what the combination does, rests on separate studies of each compound conducted years apart in different populations.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No trial or experiment has been published in which ipamorelin and CJC-1295 were given to the same subjects, either as a combination or as parallel comparator arms. Searches of PubMed and Europe PMC returned only narrative and scoping reviews of unapproved performance-enhancing peptides that discuss both compounds separately, plus anti-doping analytical methods in which both appear as target analytes in urine or plasma. Neither category generates comparative pharmacodynamic data. Any comparison is therefore indirect, drawn from a 1999 healthy-volunteer pharmacokinetic-pharmacodynamic modelling study and a 2014 postoperative ileus trial on one side, and phase I and phase II studies of the DAC-conjugated CJC-1295 conducted between 2005 and 2009 on the other, with different participants, different endpoints and no shared control.
Side by side.
| Ipamorelin | CJC-1295 | |
|---|---|---|
| Evidence maturity | Early clinical | Early clinical |
| Studies cited here | 15 | 16 |
| Published 2023 or later | 9 | 8 |
| Newest paper | 2026 | 2026 |
| Receptor target | Growth hormone secretagogue receptor 1a, the ghrelin receptor, acting at a different site from GHRH. | The GHRH receptor on the anterior pituitary, activated by an analogue of the endogenous releasing hormone. |
| Molecular design | Pentapeptide, characterised in 1998 as the first secretagogue in its class to release growth hormone with potency comparable to GHRP-6 without significantly elevating ACTH or cortisol above the levels seen after GHRH stimulation. | Two distinct molecules share the name. The DAC form carries a maleimidopropionyl linker that forms a covalent complex with circulating albumin; the non-DAC form retains only backbone modifications that resist dipeptidyl peptidase-IV cleavage. |
| Duration of action | Short-acting, with human pharmacokinetic-pharmacodynamic modelling published from a dose-escalation study in healthy volunteers in 1999. | Depends entirely on which form is meant. The DAC form has a plasma half-life of roughly one to two weeks and produced sustained GH and IGF-1 elevation; the non-DAC form has a short duration comparable to sermorelin. |
| Largest human trial | A randomised, placebo-controlled phase 2 proof-of-concept trial in 114 bowel resection patients with postoperative ileus, which did not meet its primary endpoint. Development for that indication did not proceed. | Phase I ascending single- and multiple-dose studies in healthy adults, which established dose-dependent prolonged GH and IGF-1 elevation, and a frequent-sampling study showing that GH pulsatility persisted during continuous stimulation. |
| What the human data established | Pharmacokinetic and pharmacodynamic parameters in healthy volunteers, and an absence of separation from placebo on the one clinical efficacy endpoint tested. | Endocrine surrogate endpoints only: GH concentration, IGF-1 concentration, pulsatility and serum protein profile changes. No clinical outcome endpoint has been tested. |
| Which marketed form was studied | The pentapeptide studied in the published literature is the same molecule that is sold. | Essentially all human data pertain to the DAC-conjugated compound. No peer-reviewed randomised controlled trial of the non-DAC modified GRF(1-29) form was identified, although that is the form usually described in combination material. |
| Preclinical breadth | Rat and swine pituitary work, 15-day longitudinal bone growth in rats, rodent postoperative ileus and gastric dysmotility, a ferret model of cisplatin-induced weight loss, and a cichlid fish reproductive-axis study. | Rat GRF receptor activation and pharmacokinetics, and normalisation of growth in the GHRH knockout mouse, both conducted with the DAC form. |
And what it does not.
The mechanistic rationale for pairing these compounds is coherent on paper, since they engage two different receptors that both feed the GH axis, but no published experiment has tested that rationale by giving both to the same subjects. What each literature separately supports is narrow. For CJC-1295 the human record is a handful of phase I and phase II studies from 2005 to 2009, all with the DAC-conjugated form, all measuring endocrine surrogates rather than any clinical outcome, and none addressing the non-DAC form that combination material usually describes. For ipamorelin the record is a 1999 healthy-volunteer modelling study and a randomised trial in postoperative ileus that did not separate from placebo. Neither compound has published data on body composition, lean mass, sleep, recovery or long-term safety in humans, neither holds a marketing authorisation in any jurisdiction, and both appear on the World Anti-Doping Agency Prohibited List. The literature does not establish that either compound outperforms the other, nor that the combination produces anything the separate studies did not measure.
Common questions.
- Do the two compounds work on the same receptor?
No. Ipamorelin is a selective agonist at growth hormone secretagogue receptor 1a, the ghrelin receptor. CJC-1295 in both its forms is an analogue of growth hormone-releasing hormone acting at the GHRH receptor on the anterior pituitary. The pairing is built on that difference, since the two receptors sit at separate points in the same axis, but no published study has measured what happens when both are engaged in the same subject.
- What happened in the largest randomised trial of either compound?
The largest was a prospective, randomised, placebo-controlled phase 2 proof-of-concept study of ipamorelin in 114 patients undergoing bowel resection, testing management of postoperative ileus. It did not meet its primary endpoint, and development for that indication did not continue. No randomised controlled trial has demonstrated a clinical benefit of either compound on any efficacy endpoint.
- Why does the form of CJC-1295 matter when comparing the two?
Because the two forms behave very differently and only one has been studied in humans. The DAC-conjugated form binds albumin and has a plasma half-life of roughly one to two weeks, producing sustained GH and IGF-1 elevation; that is the form used in the 2005 to 2009 phase I and phase II studies. The non-DAC form, modified GRF(1-29), has a short duration comparable to sermorelin, and no peer-reviewed randomised controlled trial of it was located.
- Did CJC-1295 disrupt the natural pattern of growth hormone release?
A frequent-sampling study in healthy adult volunteers reported that pulsatile GH secretion persisted during continuous stimulation by the DAC form, alongside the sustained elevation in mean GH and IGF-1. That finding concerns the secretion pattern measured over the study period. It says nothing about downstream body composition, performance or safety outcomes, which were not endpoints in that work.
- Is there any published evidence for the two given together?
None was located. The records that name both compounds are narrative and scoping reviews of unapproved peptides in sports medicine and endocrinology, and anti-doping analytical methods in which both appear as target analytes in urine or plasma. Neither type of publication administers the compounds or measures a combined effect.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.